Cipla is an Indian pharmaceutical company founded in 1935, known as the 'Robin Hood of drugs.' In 2001 it stunned the world by offering a three-drug anti-HIV combination—then costing $12,000 per person a year—to poor African countries and aid groups for $350 a year (under a dollar a day). Challenging the wall of patents, it opened a path for millions in the developing world to receive AIDS treatment at an affordable price. Today about one in three people living with HIV worldwide is said to be treated with a Cipla drug, and it leads the development of pediatric fixed-dose formulations. Recently it has done the same in cancer—cutting a generic of the patented drug sorafenib from $5,091 to $124 a month—declaring 'what we did for AIDS drugs, we will do for cancer.'
●●● high
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
Cipla: Life-changing AIDS and cancer drugs, at a fraction of the price, for the developing world. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
Patients in the developing world who, unable to afford a $12,000-a-year AIDS treatment, could only wait to die. Cipla's 2001 offer of anti-HIV drugs at $350 a year gave millions across Africa and South Asia access to treatment. The benefit appears as a collective: today about one in three people living with HIV worldwide is said to be treated with a Cipla drug.
Source nature: Access to Medicine Foundation / P2 Independent (reporting / Access to Medicine). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- Large price cuts for cancer drugs (sorafenib from $5,091 to $124 a month; up to 75% off across several generics).P2 Independent (reporting) / South Centre
− effects (confirmed)
- No confirmed −.
- A listed, for-profit pharmaceutical company (main business is generic/branded drugs on world markets)
- general debates over generic quality and pricing
- dependence on the US market.
- Further expanding cancer access; maintaining quality and regulatory compliance; sustaining developing-world supply; expansion into biosimilars.
A second look
The plus is access to medicines for patients in the developing world (People), backed by Access to Medicine Foundation ratings, over 20 years of work, and the concrete 'one in three.' But it is a listed, for-profit pharmaceutical company whose main business is selling generic and branded drugs on world markets, with the general debates over generic-drug quality and pricing, and dependence on the US market. Weighing the genuine, large-scale access-to-medicines plus, B/high.
Sources
How to read this assessment
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top